David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn by Côme Lepage, PUPH at the University of Bourgogne, adding:
“One more practice changing FFCD trial in colon cancer!”
Quoting Côme Lepage‘s post:
“We are very pleased to share with you the results of the Prodige-13 academic study promoted by the FFCD with its own funds, which will allow a change in practices in the surveillance of colorectal cancers operated on for curative purposes.
We would like to thank the patients and their families, and all the investigators who have taken care of and followed them for more than 10 years in 120 centers in France and Belgium.”
Title: Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer
Authors: C. Lepage, J-M Phelip, L. Cany, E. Barbier, S. Manfredi, P. Deguiral, M. Laly, M. Baconnier, M. Jary, J-P Latrive, E. Terrebonne, A. Lièvre, M. Jafari, M. Ben Abdelghani, J-F Ain, G. Breysacher, I. Boillot-Benedetto, A. Pelaquier, P. Prost, J. Ezenfis, Y. Rinaldi, C. Le Foll, O. Berthelet, A. Darut-Jouve, L. Dahan, T. Piche, J-P Lagasse, F. Bibeau, P. Laurent-Puig, O. Bouché
Read the Full Article in Science Direct.
More posts featuring Côme Lepage on OncoDaily.